Dr. Reddy’s Laboratories announces the launch of Bupropion HCl Extended-Release Tablets

Dr. Reddy’s Laboratories Ltd announced that it has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin® SR (bupropion HCl) Sustained-Release Tablets in the United States market approved by the U.S. FDA.

The Wellbutrin® SR brand and generic had U.S. sales of approximately $109.6 million MAT for the most recent twelve months ending in July 2016 according to IMS Health*.

Dr. Reddy’s Buproprion SR tablets are available in 100 mg, 150 mg and 200 mg, in bottle count sizes of 60, 100 and 500.Wellbutrin® SR is a registered trademark of the GSK group of companies.

About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd is an integrated pharmaceutical company,committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

INVESTOR RELATIONS MEDIA RELATIONS

SAUNAK SAVLA
saunaks@drreddys.com
Ph: +91-40-49002135

CALVIN PRINTER
calvinprinter@drreddys.com
Ph: +91-40- 49002121